Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial data on tipifarnib in relapsed or refractory acute myeloid leukemia have been reported with the study status marked as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6) | Phase 1 | Status: COMPLETED